This was a Phase I study for treatment with I-131 Metaiodobenzylguanidine (MIBG) in patients with metastatic carcinoid. The primary objective of the study was to determine the maximum tolerated dose of I-131 MIBG in patients with untreated metastatic carcinoid. There was documentation in the literature that patients with metastatic carcinoid, that uptake MIBG, can obtain at least subjective improvement in their disease related symptomatology with treatment using I-131 MIBG. The maximum tolerated dose had not yet been determined and that was the goal of the current study. We hoped that higher doses would improve response, both subjectively and objectively. Seventeen patients were enrolled in the study. Cohort #5 at 500 mCi of I-131 MIBG reached dose limiting toxicities with neutropenia (ANC<1500) and thrombocytopenia (<50,000) with a duration of 2 weeks or longer. These did not require hospitalization or transfusions, and no serious adverse reactions were seen. Their counts returned to normal by completion of follow-up (16 weeks). All patients showed subjective response and stable disease per CT scan. Only 3 patients received a second treatment on protocol. Three had progressive disease, 1 required surgery for tricuspid valve replacement and is stable, 14 were unable to afford further treatment due to the cost of the radioactive material or did not wish to pursue a second treatment at this time. The 3 patients that received a second treatment showed only subjective response with the first dose but did show an objective response with the second dose. No bone marrow toxicity was seen in this group of patients.

Project Start
1997-12-01
Project End
1998-11-30
Budget Start
1997-10-01
Budget End
1998-09-30
Support Year
37
Fiscal Year
1998
Total Cost
Indirect Cost
Name
Duke University
Department
Type
DUNS #
071723621
City
Durham
State
NC
Country
United States
Zip Code
27705
Askie, Lisa M; Darlow, Brian A; Finer, Neil et al. (2018) Association Between Oxygen Saturation Targeting and Death or Disability in Extremely Preterm Infants in the Neonatal Oxygenation Prospective Meta-analysis Collaboration. JAMA 319:2190-2201
Srinivasan, Lakshmi; Page, Grier; Kirpalani, Haresh et al. (2017) Genome-wide association study of sepsis in extremely premature infants. Arch Dis Child Fetal Neonatal Ed 102:F439-F445
Denson, Lee A; McDonald, Scott A; Das, Abhik et al. (2017) Early Elevation in Interleukin-6 is Associated with Reduced Growth in Extremely Low Birth Weight Infants. Am J Perinatol 34:240-247
James, Jennifer; Munson, David; DeMauro, Sara B et al. (2017) Outcomes of Preterm Infants following Discussions about Withdrawal or Withholding of Life Support. J Pediatr 190:118-123.e4
Younge, Noelle; Goldstein, Ricki F; Bann, Carla M et al. (2017) Survival and Neurodevelopmental Outcomes among Periviable Infants. N Engl J Med 376:617-628
Archer, Stephanie Wilson; Carlo, Waldemar A; Truog, William E et al. (2016) Improving publication rates in a collaborative clinical trials research network. Semin Perinatol 40:410-417
Ahmed, Zuhayer; Prasad, Indrajit; Rahman, Hafizur et al. (2016) A Male with Extreme Subcutaneous Insulin Resistance: A Case Report. Rom J Diabetes Nutr Metab Dis 23:209-213
Phelps, Dale L; Ward, Robert M; Williams, Rick L et al. (2016) Safety and pharmacokinetics of multiple dose myo-inositol in preterm infants. Pediatr Res 80:209-17
Barroso, Julie; Leserman, Jane; Harmon, James L et al. (2015) Fatigue in HIV-Infected People: A Three-Year Observational Study. J Pain Symptom Manage 50:69-79
Stafford-Smith, Mark; Li, Yi-Ju; Mathew, Joseph P et al. (2015) Genome-wide association study of acute kidney injury after coronary bypass graft surgery identifies susceptibility loci. Kidney Int 88:823-32

Showing the most recent 10 out of 128 publications